Alina Pascale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alina Pascale has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Dos Santos
INSERM, U1193, Hepatobiliary Centre, Paul Brousse Hospital, Université Paris-Saclay, 94800 Villejuif, France
1 shared publication - Antonio Sa Cunha
Hepato-Biliary Centre, Paul Brousse, AP-HP, Villejuif, Paris, France
1 shared publication - Astrid Laurent-Bellue
Department of Pathology, AP-HP Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
1 shared publication - Audrey Coilly
Centre Hépato-Biliaire, hôpital Paul-Brousse AP-HP, Université Paris-Saclay, Inserm U1193, Paris, France
1 shared publication - Catherine Guettier
Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94270 Le Kremlin-Bicêtre, France
1 shared publication - Clara Prud’homme
Department of Radiology, Paul Brousse Hospital, Université Paris Saclay, Assistance Publique-Hôpitaux de Paris (AP-HP), 94800 Villejuif, France
1 shared publication
Latest Publications
- Open Access
Identifying Subgroup at High Risk of Transarterial Chemoembolization Failure Among Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
Background/Objectives: Transarterial chemoembolization (TACE) is the most widely used bridging treatment for hepatocellular carcinoma (HCC) before liver transplantation (LT) but may be associated with dropout and post-LT HCC recurrence. We aimed to identify a subgroup of HCC LT candidates at high risk of TACE-to-LT strategy failure (TLSF). Methods: All consecutive HCC LT candidates with French AFP-scores ≤ 2 who underwent at least one bridging TACE at Paul Brousse Hospital in 2013–2018 were included (n = 173). Dropout for HCC progression during waiting list and post-LT HCC recurrence was defined TLSF. Results: The one-year TLSF cumulative incidence was 15%. According to univariate analysis, pre-TACE AFP > 15 ng/mL was the only factor associated with decreased overall survival (OS) and TLSF-free survival (TLSF-FS) after the first TACE. The absence of complete radiological response (CRR) or pre-TACE AFP > 15 ng/mL were associated with reduced OS and TLSF-FS after a second TACE (n = 118). The cumulative incidence of TLSF reached 41% one year after the second TACE in patients with both AFP > 15 ng/mL and no CRR, while it was 7% for others (p < 0.001). Conclusions: HCC patients receiving bridging TACE, with pre-TACE AFP > 15 ng/mL and no CRR after two TACEs, are at high risk of delisting for HCC progression or of post-LT recurrence. Alternative therapeutic strategies should be proposed early for this better-defined population.
Open AccessIdentifying Subgroup at High Risk of Transarterial Chemoembolization Failure Among Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
Background/Objectives: Transarterial chemoembolization (TACE) is the most widely used bridging treatment for hepatocellular carcinoma (HCC) before liver transplantation (LT) but may be associated with dropout and post-LT HCC recurrence. We aimed to identify a subgroup of HCC LT candidates at high risk of TACE-to-LT strategy failure (TLSF). Methods: All consecutive HCC LT candidates with French AFP-scores ≤ 2 who underwent at least one bridging TACE at Paul Brousse Hospital in 2013–2018 were included (n = 173). Dropout for HCC progression during waiting list and post-LT HCC recurrence was defined TLSF. Results: The one-year TLSF cumulative incidence was 15%. According to univariate analysis, pre-TACE AFP > 15 ng/mL was the only factor associated with decreased overall survival (OS) and TLSF-free survival (TLSF-FS) after the first TACE. The absence of complete radiological response (CRR) or pre-TACE AFP > 15 ng/mL were associated with reduced OS and TLSF-FS after a second TACE (n = 118). The cumulative incidence of TLSF reached 41% one year after the second TACE in patients with both AFP > 15 ng/mL and no CRR, while it was 7% for others (p < 0.001). Conclusions: HCC patients receiving bridging TACE, with pre-TACE AFP > 15 ng/mL and no CRR after two TACEs, are at high risk of delisting for HCC progression or of post-LT recurrence. Alternative therapeutic strategies should be proposed early for this better-defined population.
- 4 October 2023
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 47 (9) , 102223
New epidemiologic trends in cholangiocarcinoma
- 4 October 2023
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 47 (9) , 102223
New epidemiologic trends in cholangiocarcinoma